Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.

Cervantes-Madrid D, Szydzik J, Lind DE, Borenäs M, Bemark M, Cui J, Palmer RH, Hallberg B.

Sci Rep. 2019 Dec 18;9(1):19353. doi: 10.1038/s41598-019-55060-7.

2.

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells.

Alam MW, Borenäs M, Lind DE, Cervantes-Madrid D, Umapathy G, Palmer RH, Hallberg B.

Front Oncol. 2019 Jul 5;9:579. doi: 10.3389/fonc.2019.00579. eCollection 2019.

3.

13PPhosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.

Umapathy G, Van den Eynden J, Cervantes-Madrid D, Szydzik J, Guan J, Palmer RH, Hallberg B.

Ann Oncol. 2019 Feb 1;30(Suppl 1). pii: mdz029.006. doi: 10.1093/annonc/mdz029.006. No abstract available.

PMID:
30810197
4.

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.

Van den Eynden J, Umapathy G, Ashouri A, Cervantes-Madrid D, Szydzik J, Ruuth K, Koster J, Larsson E, Guan J, Palmer RH, Hallberg B.

Sci Signal. 2018 Nov 20;11(557). pii: eaar5680. doi: 10.1126/scisignal.aar5680.

PMID:
30459281
5.

MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.

Umapathy G, Guan J, Gustafsson DE, Javanmardi N, Cervantes-Madrid D, Djos A, Martinsson T, Palmer RH, Hallberg B.

Sci Signal. 2017 Nov 28;10(507). pii: eaam7550. doi: 10.1126/scisignal.aam7550.

PMID:
29184034
6.

Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer.

Cervantes-Madrid D, Dominguez-Gomez G, Gonzalez-Fierro A, Perez-Cardenas E, Taja-Chayeb L, Trejo-Becerril C, Duenas-Gonzalez A.

Oncol Lett. 2017 Mar;13(3):1905-1910. doi: 10.3892/ol.2017.5615. Epub 2017 Jan 18.

7.

FosB transcription factor regulates COX-2 expression in colorectal cancer cells without affecting PGE2 expression.

Cervantes-Madrid DL, Nagi S, Asting Gustafsson A.

Oncol Lett. 2017 Mar;13(3):1411-1416. doi: 10.3892/ol.2017.5571. Epub 2017 Jan 4.

8.

DNA alterations in Cd133+ and Cd133- tumour cells enriched from intra-operative human colon tumour biopsies.

Cervantes-Madrid D, Wettergren Y, Falk P, Lundholm K, Asting AG.

BMC Cancer. 2017 Mar 27;17(1):219. doi: 10.1186/s12885-017-3206-8.

9.

Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.

Cervantes-Madrid D, Romero Y, Dueñas-González A.

Biomed Res Int. 2015;2015:690492. doi: 10.1155/2015/690492. Epub 2015 Sep 6. Review.

10.

Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids.

Cervantes-Madrid D, Dueñas-González A.

Oncol Rep. 2015 Sep;34(3):1533-42. doi: 10.3892/or.2015.4077. Epub 2015 Jun 24.

PMID:
26134042
11.

Emerging drugs for cervical cancer.

Dueñas-Gonzalez A, Cetina L, Coronel J, Cervantes-Madrid D.

Expert Opin Emerg Drugs. 2012 Jun;17(2):203-18. doi: 10.1517/14728214.2012.683409. Epub 2012 Apr 25. Review.

PMID:
22530838

Supplemental Content

Loading ...
Support Center